Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

BioFocus signs agreement with Biogen Idec in target discovery for scleroderma

Nov. 13, 2013

Clinuvel Pharmaceuticals reports data from U.S. phase III study of Scenesse

Nov. 12, 2013

Aclaris Therapeutics begins IND-directed program for A-101

Nov. 8, 2013

Cimzia gets positive opinion for PsA and approval for severe active axial spondyloarthritis

Oct. 29, 2013

Rigel provides update on two pipeline candidates

Oct. 29, 2013

Tissue Therapies files application to conduct pivotal VitroGro ECM trial

Oct. 28, 2013

Auxilium begins phase IIa study of Xiaflex for treatment of cellulite

Oct. 25, 2013

FDA accepts supplemental BLA filing for Xolair

Oct. 14, 2013

Pergamum reports final data from phase I/II LL-37 study in chronic leg ulcers

Oct. 11, 2013

Edimer begins phase II trial in XLHED-affected male newborns

Oct. 9, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...